Abstract: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
Type:
Grant
Filed:
August 7, 2007
Date of Patent:
March 15, 2011
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Juan Francisco Caturla Javaloyes, Laura Vidal Gispert, Wenceslao Lumeras Amador
Abstract: A compound of formula (I) is provided, wherein B, A, R1, R2, R3, R4, R5 and R6 are as defined herein and X? represents a pharmaceutically acceptable anion of a mono or polyvalent acid. Processes for the preparation of such compounds and pharmaceutical compositions containing them are also provided.
Type:
Grant
Filed:
August 31, 2006
Date of Patent:
February 22, 2011
Assignee:
Almirall, S.A.
Inventors:
Maria Prat Quinones, Maria Dolors Fernandez Forner, Maria Antonia Buil Albero
Abstract: A compound of formula (I) is provided, wherein B, A, R1, R2, R3, R4, R5 and R6 are as defined herein and X? represents a pharmaceutically acceptable anion of a mono or polyvalent acid. Processes for the preparation of such compounds and pharmaceutical compositions containing them are also provided. group or a —CH2OH group; and X? represents a pharmaceutically acceptable anion of a mono or polyvalent acid.
Type:
Grant
Filed:
August 31, 2006
Date of Patent:
February 1, 2011
Assignee:
Almirall, S.A.
Inventors:
Maria Prat Quinones, Maria Dolors Fernandez Forner, Maria Antonia Buil Albero
Abstract: The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
December 21, 2010
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Bernat Vidal Juan, Silvia Fonquerna Pou, Paul Robert Eastwood, Jose Aiguade Bosch, Aranzazu Cardus Figueras, Ines Carranco Moruno, Jacob Gonzalez Rodriguez, Sergio Paredes Aparicio
Abstract: The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R1 and R2 are chosen from a hydrogen atom and specified substituents, or b) R2, R1 and the —NH— group to which R1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.
Type:
Grant
Filed:
July 25, 2006
Date of Patent:
September 7, 2010
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Bernat Vidal Juan, Christina Esteve Trias, Lidia Soca Pueyo, Paul Robert Eastwood
Abstract: A carbamate of formula (I), wherein R1 represents wherein R2 represents a benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl or thiophen-3-ylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbon atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p is 1 or 2 and the substitution in the azoniabicylic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt may be of formula (II).
Type:
Grant
Filed:
June 5, 2007
Date of Patent:
August 17, 2010
Assignee:
Almirall, S.A.
Inventors:
Maria Antonia Buil Albero, Maria Dolors Fernandez Forner, Maria Prat Quinones
Abstract: The present relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.
Type:
Application
Filed:
October 17, 2007
Publication date:
July 1, 2010
Applicant:
LABORATORIOS ALMIRALL, S.A.
Inventors:
Jordi Bach Tanã, Maria Isabel Crespo, Carlos Puig Duran, Silvia Gual Roig, Alberto Ortega Münoz
Abstract: New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.
Abstract: The present disclosure relates to compounds of formula (I): or a pharmaceutically acceptable salt or N-oxide thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.
Type:
Application
Filed:
December 21, 2007
Publication date:
March 25, 2010
Applicant:
LABORATORIOS ALMIRALL, S.A.
Inventors:
Julio Cesar Castro Palomino Laria, Montserrat Erra Sola, Maria Estrella Lozoya Toribio, Eloisa Navarro Romero
Abstract: New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed, as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.
Type:
Grant
Filed:
January 23, 2004
Date of Patent:
February 16, 2010
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Emma Terricabras Belart, Victor Manuel Segarra Matamoros, Julio Alvarez-Builla Gomez, Juan Jose Vaquero Lopez, Jose Miguel Minguez Ortega
Abstract: To provide an inhalation device which has improved use properties, particularly advanced moisture protection while in use, an inhalation device (1) for powder drugs is proposed comprising at least one storage chamber (13) for accommodating a plurality of drug powder doses and a dosing device which includes at least one dosing slider (15) which is movable approximately with a translatory movement in a dosing slider passage (16) at least from a filling position into an emptying position, wherein the inhalation device (1) further includes a device for inhalation-triggered automatic movement of the dosing slider (15) from its filling position into the emptying position and a return device for automatic movement of the dosing slider (15) back into the filling position.
Type:
Application
Filed:
December 21, 2007
Publication date:
January 21, 2010
Applicant:
LABORATORIOS ALMIRALL, S.A.
Inventors:
Martin Herder, Gerhard Ludanek, Ingo Mett
Abstract: This invention is directed to selective antagonists of H1 histamine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
Type:
Grant
Filed:
April 1, 2003
Date of Patent:
November 24, 2009
Assignee:
Laboratorios Almirall S.A.
Inventors:
Silvia Fonquerna Pou, Luis Miguel Pages Santacana, Carlos Puig Duran, Jose Manuel Prieto Soto, Aranzazu Cardus Figueras
Abstract: The present invention relates to 2-phenylpyran-4-derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses.
Type:
Grant
Filed:
February 12, 2004
Date of Patent:
September 1, 2009
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Juan Francisco Caturla Javaloyes, Graham Warrellow
Abstract: This invention is directed to new potent and selective antagonists of H1 histamine receptors having the general formula I to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy as antiallergic agents.
Type:
Grant
Filed:
May 19, 2003
Date of Patent:
July 14, 2009
Assignee:
Laboratorios Almirall S.A.
Inventors:
Silvia Fonquerna Pou, Luis Miguel Pages Santacana
Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are provided as well as processes for the manufacture of such compounds. The compounds are useful in the treatment or prevention of inflammatory and allergic diseases.
Type:
Grant
Filed:
November 11, 2003
Date of Patent:
July 7, 2009
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Carlos Puig Duran, Daniel Perez Crespo, Jordi Bach Tana, Hamish Ryder
Abstract: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receplors which is (3R)-1-phencthyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octanc, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.
Type:
Application
Filed:
December 16, 2008
Publication date:
April 9, 2009
Applicant:
Laboratorios Almirall, S.A.
Inventors:
Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
Abstract: New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.
Type:
Grant
Filed:
November 8, 2004
Date of Patent:
March 31, 2009
Assignee:
Laboratorios Almirall S.A.
Inventors:
Vittorio Dal Piaz, Nuria Aguilar Izquierdo, Maria Antonia Buil Albero, Yolanda Garrido Rubio, Maria Paola Giovannoni, Jordi Gracia Ferrer, Wenceslao Lumeras Amador, Claudia Vergelli
Abstract: This invention is directed to selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
Abstract: Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4. R1, R2 and R4 are organic radicals, R3 is a cyclic group, and R5 is an ester or an aryl or heteroaryl group.
Type:
Grant
Filed:
December 22, 2003
Date of Patent:
February 17, 2009
Assignee:
Laboratorios Almirall S.A.
Inventors:
Vittorio Dal Piaz, Nuria Aguilar Izquierdo, Maria Antonia Buil Albero, Marta Carrascal Riera, Jordi Gracia Ferrer, Maria Paola Giovannoni, Claudia Vergelli
Abstract: New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors.